Cargando…

Identification of adenoid subtype characterized with immune-escaped phenotype in lung squamous carcinoma based on transcriptomics

Non-small cell lung cancer (NSCLC) is a heterogeneous disease, and its demarcation contributes to various therapeutic outcomes. However, a small subset of tumors shows different molecular features that are in contradiction with pathological classification. Unsupervised clustering was performed to su...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Jie, Cai, Yun, Mussafi, Ofek, Zheng, Mingfeng, Xu, Yongrui, Chen, Ruo, Jiang, Guanyu, Mao, Wenjun, Xia, Wei, Wan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555124/
https://www.ncbi.nlm.nih.gov/pubmed/36224612
http://dx.doi.org/10.1186/s40164-022-00327-5
Descripción
Sumario:Non-small cell lung cancer (NSCLC) is a heterogeneous disease, and its demarcation contributes to various therapeutic outcomes. However, a small subset of tumors shows different molecular features that are in contradiction with pathological classification. Unsupervised clustering was performed to subtype NSCLC using the transcriptome data from the TCGA database. Next, immune microenvironment features of lung adenocarcinoma (LUAD), lung squamous carcinoma (LUSC), and lung adenoid squamous carcinoma (LASC) were characterized. In addition, diagnostic biomarkers to demarcate LASC among LUSC were screened using weighted gene co-expression network analysis (WGCNA) and validated by the in-house cohort. LASC was identified as a novel subtype with adenoid transcriptomic features in LUSC, which exhibited the most immuno-escaped phenotype among all NSCLC subtypes. In addition, FOLR1 was identified as a biomarker for LASC discrimination using the WGCNA analysis, and its diagnostic value was validated by the in-house cohort. Moreover, FOLR1 was related to immuno-escaped tumors in LUSC but not in LUAD. Overall, we proposed a novel typing strategy in NSCLC and identified FOLR1 as a biomarker for LASC discrimination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-022-00327-5.